Diatrizoate Meglumine

Table of Contents > Drugs > Diatrizoate Meglumine

	Pronunciation
	U.S. Brand Names
	Generic Available
	Use
	Pregnancy Risk Factor

	Pregnancy Implications
	Lactation
	Contraindications
	Dosage Forms
	References

Pronunciation

(dye a tri ZOE ate MEG loo meen)

U.S. Brand Names

Cystografin®; Cystografin® Dilute; Hypaque-Cysto™; Hypaque™ Meglumine; Reno-30®; Reno-60®; Reno-Dip®

Generic Available

Use

Solution for instillation: Retrograde cystourethrography; retrograde or ascending pyelography

Solution for injection: Arthrography, cerebral angiography, direct cholangiography, discography, drip infusion pyelography, excretory urography, peripheral arteriography, splenoportography, venography; contrast enhancement of computed tomographic head imaging

Pregnancy Risk Factor

Pregnancy Implications

Animal reproduction studies have not been conducted. Diatrizoate salts cross the placenta and may enter fetal circulation. Abnormal neonatal opacification of the small intestine and colon have been reported in the newborn 4-6 days after delivery. In general, iodinated contrast media agents are avoided during pregnancy unless essential for diagnosis.

Lactation

Enters breast milk/use caution

Contraindications

Hypersensitivity to diatrizoate or any component of the formulation; solutions for instillation should not be used for intravascular injection; solutions for injection are not for intrathecal use

Refer to product labeling for procedure-specific contraindications.

Dosage Forms

Solution, for instillation:

Cystografin®: Diatrizoate meglumine 30% (100 mL, 300 mL) [provides organically-bound iodine 141 mg/mL; contains edetate disodium]

Cystografin® Dilute: Diatrizoate meglumine 18% (300 mL) [provides organically-bound iodine 85 mg/mL; contains edetate disodium]

Reno-30®: Diatrizoate meglumine 30% (50 mL) [provides organically-bound iodine 141 mg/mL; contains edetate disodium]

Solution, for instillation [preservative free] (Hypaque-Cysto™): Diatrizoate meglumine 30% (250 mL) [provides organically-bound iodine 141 mg/mL; contains edetate calcium disodium]

Solution, injection:

Hypaque™ Meglumine: Diatrizoate meglumine 60% (50 mL, 100 mL, 150 mL, 200 mL) [provides organically-bound iodine 282 mg/mL; contains edetate calcium disodium]

Reno-60®: Diatrizoate meglumine 60% (10 mL, 50 mL, 100 mL, 150 mL) [provides organically-bound iodine 282 mg/mL; contains edetate disodium, sodium 0.91 mg (0.04 mEq)/mL]

Reno-Dip®: Diatrizoate meglumine 30% (300 mL) [provides organically-bound iodine 141 mg/mL; contains edetate disodium, sodium 0.049 mg (0.002 mEq)/mL]

References

ACOG Committee on Obstetric Practice, "ACOG Committee Opinion. Guidelines for Diagnostic Imaging During Pregnancy,"Obstet Gynecol, 2004, 104(3):647-51.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.